Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer

Human Gene Therapy

Volumn 10, Issue 17, 1999, Pages 2757-2768

  Todryk, Stephen ^a   McLean, Cornelia ^b   Ali, Selman ^c   Entwistle, Claire ^b   Boursnell, Michael ^b   Rees, Robert ^c   Vile, Richard ^a,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; CANCER VACCINES; COLORECTAL NEOPLASMS; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NECROSIS; NEOPLASM TRANSPLANTATION; SIMPLEXVIRUS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0033589748     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016492     Document Type: Article

References (31)

1. ALLIONE, A., CONSALVO, M., NANNI, P., LOLLINI, P.L., CAVALLO, F., GIOVARELLI, M., FORNI, M., GULINO, A., COLOMBO, M.P., DALLABONA, P., HOCK, H., BLANKENSTEIN, T., ROSENTHAL, F.M., GANSBACHER, B., BOSCO, M.C., MUSSO, T., GUSELLA, L., and FORNI, G. (1994). Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
2. BLOTTIERE, H.M., ZENNADI, R., GREGOIRE, M., AILLET, G., DENIS, M.G., MEFLAH, K., and LE PENDU, J. (1993). Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. Int. J. Cancer 53, 409-417.
3. BOURSNELL, M.E.G., ENTWISLE, C., BLAKELEY, D., ROBERTS, C., DUNCAN, I.A., CHISHOLM, S.E., MARTIN, G.M., JENNINGS, R., NI CHALLNAIN, D., SOBEK, I., INGLIS, S.C., and McLEAN, C.S. (1997). A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175, 16-25.
4. BRATTAIN, M.G., STROBEL-STEVENS, J., FINE, D., WEBB, M., and SARRIF, A.M. (1980). Establishment of mouse colonic embryonic carcinoma cell lines with different metastatic properties. Cancer Res. 40, 2142-2146.
5. CASTLEDEN, S.A., CHONG, H., GARCIA-RIBAS, I., MELCHER, A.A., HUTCHINSON, G., ROBERTS, B., HART, I.R., and VILE, R.G. (1997). A family of bicistronic vectors to enhance both local and systemic anti tumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther. 8, 2087-2102.
6. CHONG, H., TODRYK, S., HUTCHINSON, G., HART, I.R., and VILE, R.G. (1998). Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther. 5, 223-232.
7. COLOMBO, M.P., MODESTI, A., PARMIANI, G., and FORNI, G. (1992). Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52, 4853-5857.
8. DIAZ, R.M., TODRYK, S., CHONG, H., HART, I.R., SIKORA, K., DORUDI, S., and VILE, R.G. (1998). Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther. 5, 869-879.
9. DIGIORGIO, A., BOTTI, C., TOCCHI, A., MINGAZZINI, P., and FLAMMIA, M. (1992). The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int. Surg. 77, 256-260.
10. DILLOO, D., RILL, DL, ENTWISTLE, C., BOURSNELL, M., ZHONG, W., HOLDEN, W., HOLLADAY, M., INGLIS, S., and BRENNER, M. (1997). A novel herpes vector for the high-efficiency transduction of normal and malignant human haemopoietic cells. Blood 89, 119-127.
11. DRANOFF, G., JAFFEE, E.M., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HIROFUMI, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
12. FOSSUM, B., OLSEN, A.C., THORSBY, E., and GAUDERNACK, G. (1995). CDS+ T cells from a patient with colon carcinoma, specific fora mutant p21-ras-derived peptide (Gly13-Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol. Immunother. 40, 165-172.
13. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
14. GANSBACHER, B., HOUGHTON, A., LIVINGSTON, P., MINASIAN, L., ROSENTHAL, F., GILBOA, E., GOLDE, D., OETTGEN, H., STEFFANS, T., YANG, S.Y., and WONG, G. (1992). Clinical protocol: A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum. Gene Ther. 3, 677-690.
15. HICKLING, J.K., CHISHOLM, S.E., DUNCAN, I.E., TAYLOR, E.J., BOSWELL, C., McLEAN, C.S., UTTRIDGE, J., ROBERTS, J.S.C., TOMASI, A., STANBERRY, L., BERNSTEIN, D.I., BOURSNELL, M.E.G., and INGLIS, S.C. (1998). Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in phase 1 clinical trials in HSV-2 seropositive and seronegative volunteers. In 8th International Congress on Infectious Diseases. [Abstract 22.008]
16. HUANG, A.Y.C., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
17. KIM, J.A., MARTIN, E., JR., MORGAN, C.J., ALDRICH, W., and TRIOZZI, P.L. (1995). Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer. Cancer Biother. 10, 115-123.
18. MATZINGER, P. (1998). An innate sense of danger. Semin. Immunol. 10, 399-415.
19. MELCHER, A., TODRYK, S., HARDWICK, N., FORD, M., JACOBSON, M., and VILE, R.G. (1998). Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein. Nature Med. 4, 581-587.
20. PARDOLL, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415.
21. SIMONS, J.W., JAFFEE, E.M., WEBER, C.E., LEVITSKY, H.I., NELSON, W.O., CARDUCCI, M.A., LAZENBY, A.J., COHEN, L.K., FINN, C.C., CLIFT, S.M., HAUDA, K.M., BECK, L.A., LEIFERMAN, K.M., OWENS, A.H., PIANTADOSI, S., DRANOFF, G., MULLIGAN, R.C., PARDOLL, D.M., and MARSHAL, F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex-vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546.
22. SOIFFER, R., LYNCH, T., MIHM, M., JUNG, K., RHUDA, C., SCHMOLLINGER, J.C., HODI, F.S., LIEBSTER, L., LAN, P., MENTZER, S., SINGER, S., NEUBERG, D., PARRY, G., ROKOVICH, J., RICHARDS, L., DRAYER, J., BERNS, A., CLIFT, S., COHEN, L.K., MULLIGAN, R.C., and DRANOFF, G. (1998). Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 95, 13141-13146.
23. ST. CLAIR ROBERTS, J., UTTRIDGE, J.A., HICKLING, J.K., LOUDON, P.T., McLEAN, C.S., BOURSNELL, M.E.G., INGLIS, S.C., BELLI, J.A., BERNSTEIN, D.I., and STANBERRY, L. (1998). Safety, tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase I clinical trials in HSV-2 seropositive and seronegative volunteers. In 8th International Congress of Infectious Diseases. [Abstract 22.009]
24. SVENNEVIG, J.L., LUNDE, O.C., HOLTER, J., and BJORGSVIK, D. (1984). Lymphoid infiltration and prognosis in colorectal carcinoma. Br. J. Cancer 49, 375-377.
25. TODRYK, S.M., CHONG, H., PANDHA, H., LEMOINE, N.R., and VILE, R.G. (1998). Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut 43, 445-449.
26. TSANG, K.Y., ZAREMBA, S., NIERODA, C.A., ZHU, M.Z., HAMILTON, J.M., and SCHLOM, J. (1995). Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87, 982-990.
27. VERMORKEN, J.B., CLAESSEN, A.M.E., VAN TINTEREN, H., GALL, H.E., EZINGA, R., MEIJER, S., SCHEPER, R.J., MEIJER, C.J.L.M., BLOEMENA, E., RANSOM, J.H., HANNA, M.G., JR., and PINEDO, H.M. (1999). Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353, 345-350.
28. VILE, R.G., and CHONG, H. (1996). Immunotherapy: Combinatorial molecular immunotherapy - a synthesis and suggestions. Cancer Metastasis Rev. 15, 351-364.
29. VILE, R., and RUSSELL, S.J. (1994). Gene transfer technologies for the gene therapy of cancer. Gene Ther. 1, 88-98.
30. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I.R. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.
31. VILE, R.G., CASTLEDEN, S.C., MARSHALL, J., CAMPLEJOHN, R., UPTON, C., and CHONG, H. (1997). Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71, 267-274.